Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22056Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nakou, E. | en |
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.contributor.author | Tselepis, A. D. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Mikhailidis, D. P. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:20:42Z | - |
| dc.date.available | 2015-11-24T19:20:42Z | - |
| dc.identifier.issn | 1744-7666 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22056 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Antihypertensive Agents/administration & dosage/*therapeutic use | en |
| dc.subject | Appetite Depressants/administration & dosage/*therapeutic use | en |
| dc.subject | Blood Pressure/drug effects | en |
| dc.subject | Body Weights and Measures | en |
| dc.subject | C-Reactive Protein/analysis | en |
| dc.subject | Cyclobutanes/administration & dosage/*therapeutic use | en |
| dc.subject | Delayed-Action Preparations | en |
| dc.subject | Diet | en |
| dc.subject | Drug Combinations | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Female | en |
| dc.subject | Heart Rate/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension/complications/*drug therapy | en |
| dc.subject | Indoles/administration & dosage/*therapeutic use | en |
| dc.subject | Lipids/blood | en |
| dc.subject | Male | en |
| dc.subject | Nicotinamide Phosphoribosyltransferase/drug effects | en |
| dc.subject | Obesity/complications/*drug therapy | en |
| dc.subject | Verapamil/administration & dosage/*therapeutic use | en |
| dc.title | Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1517/14656566.9.10.1629 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/18570597 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.1517/14656566.9.10.1629 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | OBJECTIVE: The management of obese hypertensive subjects may require the administration of anti-obesity and antihypertensive drugs. Sibutramine use has raised concerns regarding a potential increase in subjects' blood pressure and heart rate. The primary end-points of this study were an evaluation of the effect of sibutramine together with a verapamil sustained release/trandolapril combination tablet versus verapamil sustained release/trandolapril alone on the blood pressure and heart rate in obese hypertensive patients. RESEARCH DESIGN/METHODS: Patients received a low-fat low-calorie diet and were randomly allocated to open-label verapamil sustained release/trandolapril 180/2 mg (n = 26) or sibutramine 10 mg together with verapamil sustained release/trandolapril 180/2 mg (n = 28) daily for 6 months. RESULTS: Significant reductions in the subjects' systolic blood pressure and diastolic blood pressure were observed in both groups (p < 0.01 versus baseline). At 6 months a greater fall in blood pressure was observed in the sibutramine/verapamil sustained release/trandolapril group compared with the verapamil sustained release/trandolapril group (systolic blood pressure 21.9 +/- 8.1 versus 15.9 +/- 12.3 mmHg and diastolic blood pressure 15.7 +/- 8.1 versus 9.1 +/- 9.9 mmHg) but this was only significant (p = 0.03) for diastolic blood pressure. The subjects' heart rate did not change significantly in any group. No significant sibutramine-associated attenuation of blood pressure reduction was observed during the study. The sibutramine/verapamil sustained release/trandolapril treatment resulted in significantly greater improvement in the subjects' anthropometric variables, homeostasis model assessment and lipid profiles compared with verapamil sustained release/trandolapril administration. The subjects' small dense low-density lipoprotein cholesterol, high-sensitivity C-reactive protein and visfatin plasma levels were only measured in the sibutramine/verapamil sustained release/trandolapril group (all decreased by p < 0.05 versus baseline). CONCLUSIONS: The sibutramine/verapamil sustained release/trandolapril combination in obese hypertensive patients significantly reduced their blood pressure and improved their anthropometric and metabolic variables without affecting the heart rate. | en |
| heal.journalName | Expert Opin Pharmacother | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
